(Q35675040)

9 August 2017

0 references

1 reference

title

Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia (English)

1 reference

chronic obstructive pulmonary disease

9 August 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113207%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Adamantia Liapikou

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113207%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Michael Toumbis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113207%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

25 June 2015

1 reference

Expert Opinion on Drug Safety

9 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113207%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113207%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113207%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

1237-1247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113207%20AND%20SRC:MED&resulttype=core&format=json

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Pharmacotherapy and the risk for community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

The natural history of community-acquired pneumonia in COPD patients: a population database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Reported pneumonia in patients with COPD: findings from the INSPIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Inhaled drugs as risk factors for community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Macrophage activation in exacerbated COPD with and without community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Fluticasone propionate reduces bacterial airway epithelial invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Inhaled corticosteroids in COPD: the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Methods for therapeutic trials in COPD: lessons from the TORCH trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Effect of bronchial colonisation on airway and systemic inflammation in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Clinical COPD phenotypes: a novel approach using principal component and cluster analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Update on clinical inflammometry for the management of airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Distinct clinical phenotypes of airways disease defined by cluster analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Risks of pneumonia in patients with asthma taking inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494

Variability and effects of bronchial colonisation in patients with moderate COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1057494